Natalie Callander, MD

Articles

Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

November 1st 2024

Panelists discuss the currently available chimeric antigen receptor T-cell therapies for early relapse multiple myeloma, examining their place within the treatment paradigm and how factors such as product type (cilta-cel vs ide-cel) and high-risk features (such as minimal residual disease positivity post induction and extramedullary disease) influence clinical decision-making.

Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

November 1st 2024

Panelists discuss the key disease and patient factors considered when choosing between triplet and quadruplet induction regimens for patients with transplant-ineligible multiple myeloma, as well as the unmet needs that persist in the treatment landscape for both transplant-eligible and ineligible populations.

Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

October 25th 2024

Panelists discuss the CEPHEUS trial results for newly diagnosed patients who are not transplant eligible, highlighting key takeaways. They also compare the CEPHEUS data with other quadruplet regimens in the non–transplant-eligible space, such as Isa-VRd.

MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

October 25th 2024

Panelists discuss the importance of minimal residual disease negativity as a primary outcome measure and the treatment strategies for patients who are eligible for transplantation but choose to decline it, including preferred induction regimens for this population.

Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

October 18th 2024

Panelists discuss whether daratumumab quadruplet induction regimens should be considered the new standard of care for newly diagnosed transplant-eligible patients and explore scenarios in which a triplet induction regimen might still be appropriate. They also review the findings from the ISKIA and GMMG-CONCEPT trials, including considerations for using isatuximab-carfilzomib (IsaKRd) over D-VRd.

Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

October 18th 2024

Panelists discuss the findings of the PERSEUS trial and the recent cytogenetic risk analysis for patients with newly diagnosed transplant-eligible multiple myeloma. They then explore the CASSIOPEIA trial and its implications regarding daratumumab quadruplet induction regimens.

BCMA-Targeting Therapies for RRMM: Future Perspectives

March 28th 2022

Considerations for optimizing treatment with BCMA-targeting agents for patients with relapsed/refractory multiple myeloma moving forward.

Sequencing BCMA-Targeted Therapies in RRMM

March 28th 2022

Current combination approaches, including BCMA-targeting agents like belantamab mafodotin, being explored to address treatment gaps in relapsed/refractory multiple myeloma.

BCMA-Targeting Bispecifics for the Treatment of RRMM

March 28th 2022

An overview of novel bispecific therapies under development in relapsed/refractory multiple myeloma.

CAR T-Cell Therapy for RRMM

March 21st 2022

Implications for treating patients with relapsed/refractory multiple myeloma with CAR T cells vs antibody-drug conjugates.

Treatment of Keratopathy Associated with Belantamab Mafodotin

March 21st 2022

Recommendations for managing ocular toxicities associated with belantamab mafodotin when used as treatment for relapsed/refractory multiple myeloma.

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin plus Inducible T-cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

March 14th 2022

Dr. Natalie Callander reviews data from the DREAMM-5 study presented at ASH 2021, which assessed the safety and efficacy of belantamab mafodotin plus feladilimab in patients with relapsed/refractory multiple myeloma with disease resistance to at least 3 prior lines of therapy.

Belantamab Mafodotin Dosing Strategies in Patients with RRMM

March 14th 2022

What to know in terms of dosing belantamab mafodotin treatment in patients with relapsed/refractory multiple myeloma.

Selecting Appropriate Treatment for Patients With Heavily Pretreated Multiple Myeloma

March 14th 2022

Variables that impact treatment decisions for relapsed/refractory multiple myeloma.

Management of a 61-Year-Old Female With Heavily Pretreated RRMM

March 8th 2022

Natalie Callander, MD, presents the profile of a female patient with relapsed/refractory multiple myeloma who receives belantamab mafodotin and develops keratopathy.

Safety of Belantamab Mafodotin in Patients With RRMM

March 8th 2022

Karen L. Klugo, MD, describes what’s unique in terms of patient response to belantamab mafodotin as treatment for relapsed/refractory multiple myeloma and risk of ocular disease.

BCMA-Targeting Belantamab Mafodotin: Role in the Treatment Landscape of RRMM

February 28th 2022

The rationale for treating relapsed/refractory multiple myeloma with belantamab mafodotin, and studies investigating the drug’s potential in earlier treatment settings.

Treatment Approach for a 57-Year-Old Man With Triple-Class Refractory MM

February 28th 2022

Sagar Lonial, MD, FACP, highlights a novel treatment option available for a 57-year-old man whose disease progresses after 3 prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.